2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

Memo

<p>Following the success of the first iCDP summit last year, we are returning this September to provide the primary industry platform for the advancement of cannabinoid-derived pharmaceuticals. When this summit takes place it will have been just over a year since GW Pharmaceutical's created the first FDA approved drug containing a cannabinoid API, and several contenders are hot on their heels. However, there are many challenges still obstructing the development of this generation of cannabinoid pharmaceuticals.</p><p>Join your peers at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit to solve your challenges in this fast growing field, and to maximise the potential of the next-generation of cannabinoid pharmaceuticals.</p><p>*Early booking and group discounts are available upon request. For more details visit our website for the full pricing list.</p><p>&nbsp;</p><p>On Tuesday September 10, 2019 at 8:20 am (ends Thursday September 12, 2019 at 4:10 pm)</p><p>&nbsp;</p><p>Venue details:<br />Aloft Boston Seaport District, 401-403 D Street, Boston, 02210, United States</p><p>&nbsp;</p><p>Price:<br />Conference + 2 Workshops: USD 3097.0,<br />Conference + 1 Workshops: USD 2598.0,<br />Conference Only: USD 2099.0,<br />Workshops Only: USD 599.0</p><p>Speakers: Guy Chamberland, Chief Executive Officer, Tetra Biopharma, Dennis Ahern, Vice President, Global Regulatory Affairs, Greenwich Biosciences, Mara Gordon, Founder &amp; Director, Zelda Therapeutics, Brian Murphy, Chief Executive Officer, Emerald Biopharma, Sara Ward, Researcher, Oncology, Temple University, Ethan Russo, Professor, International Cannabis and Cannabinoids Institute, Andrea Small-Howard, Chief Science Officer, GB Sciences, Robert Walsh, Chief of Regulatory Affairs Branch Division of Therapeutics &amp; Medical Consequences of Drug Abuse,NIDA, Sagnik Bhattacharyya, Reader of Translational Neuroscience &amp; Psychiatry, King's College London</p>